[19]
In the normal course, where a second person seeks to compare its drug to that of a first person in the hope of facilitating the issuance of an NOC, it will want to disclose as clearly as possible those facts relating to its process which distinguish it from the process used by the first person. (Contrary to what is suggested by the respondent, confidentiality of the process cannot be an obstacle to disclosure in light of the wide range of protective orders which this court is empowered to grant.) That in turn will compel the first person to assume the burden of establishing on a preponderance of the evidence that the allegation of noninfringement has not been made out.